|
||
|
| Home |  |
Firm Description | |
Sectors Covered | |
Completed Transactions | |
Testimonials | |
Principals | |
M&A Report and Publications |
|
Contact Us | |
| Acquiring Party | Shire plc (LSE: SHP.L ; NASDAQ: SHPG ), a British specialty pharmaceutical company focused on attention deficit and hyperactivity disorder (ADHD), human genetic therapies, gastrointestinal and renal diseases. |
|---|---|
| Transferring Party | New River Pharmaceuticals Inc. (NASADQ), a U.S. drug maker specializing in ADHD. |
| Sector | Biopharmaceuticals |
| Date | April 20, 2007 |
| Analysis Shire can now drive the launch and future development, and gain the full economic benefits, of key new ADHD drugs. Strengthens Shire's position in the growing US ADHD market, improves its operating margins, adds to its pipeline, and enhances its earnings growth potential. Deal value - $2.6b. | |
The Walden Group is a leading healthcare investment banking firm specializing in mergers, acquisitions and strategic transactions. It also invests its own funds and, together with its expert operational partners, provides value-added services to help special companies reach critical milestones. This information is copyright © 2004-2007 The Walden Group, Inc. This information is provided as a service to the public but remains the intellectual property of The Walden Group, Inc and may not be reproduced in any manner without the written permission of The Walden Group, Inc. The information contained in the transactions table was derived from publicly available and other sources. Transaction analysis and other information are based, in part, upon public comments, Walden Group research and judgments, and reporting and research of others. The information is not intended to be relied upon as pronouncements by the transaction participants or for any other reason. | |